Search
Bioventus Inc
BVSAdd to Watchlist
12.910USD
+0.280+2.22%
Close 09-17 16:00（ET）
879.25MMarket Cap
30.16P/E TTM
More Details of Bioventus Inc Company
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Bioventus Inc Profile
Ticker SymbolBVS
Company nameBioventus Inc
IPO dateFeb 11, 2021
CEOClaypoole (Robert E)
Number of employees930
Security typeOrdinary Share
Fiscal year-endFeb 11
Address4721 Emperor Boulevard, Suite 100
CityDURHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27703
Phone19194746700
Websitehttps://www.bioventus.com/
Ticker SymbolBVS
IPO dateFeb 11, 2021
CEOClaypoole (Robert E)
Company Executives of Bioventus Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Mr. Anthony (Tony) D'Adamio, J.D.
Mr. Anthony (Tony) D'Adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
153.66K
+1.73%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
FAQs
Who are the top five shareholders of Bioventus Inc?
The top five shareholders of Bioventus Inc are: Mr. Anthony (Tony) D'Adamio, J.D.
How many institutions hold shares of Bioventus Inc (BVS)?
As of 2026Q1, 339 institutions hold shares of Bioventus Inc, with a combined market value of approximately 52.51M, accounting for 77.51% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -10203484.00.
What is the biggest source of revenue for Bioventus Inc?
In 2026Q1, the Pain Treatments business generated the highest revenue for Bioventus Inc, amounting to 81.75M and accounting for 53.36% of total revenue.